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Background: Osteoporosis is common in advanced COPD and worsens rapidly after transplanta-
tion, potentially impairing quality of life. Increased high density lipoprotein cholesterol (HDLc)
has been observed in COPD and linked with osteoporosis in the general population. This asso-
ciation has not been previously examined in COPD.
Methods: We reviewed the records of 245 COPD patients referred for lung transplant evalua-
tion. Osteoporosis was defined by either dual energy X-ray absorptiometry scan or use of oste-
oporosis medications. The presence or absence of osteoporosis could be ascertained in 152
subjects. Cholesterol values and other clinical variables were assessed for their association
with osteoporosis.
Results: Clinical factors associated with osteoporosis included lower BMI [OR 0.81, 95% CI
0.73e0.90], higher HDLc [OR 1.04, 95% CI 1.02 to 1.07], and worse lung function. HDLc was
an independent predictor of OP and demonstrated an inverse linear correlation with T-scores
(r Z 0.21, p Z 0.05), which was stronger amongst males (r Z 0.45, p Z 0.004).
Conclusion: In COPD patients referred for lung transplantation, osteoporosis is highly preva-
lent. Raised HDLc levels are common in this group and are independently associated with OP.
ª 2010 Elsevier Ltd. All rights reserved.nsity; BMI, Body mass index; CAD, Coronary artery disease; COPD, Chronic obstructive pulmonary
DXA, Dual x-ray absorptiometry; HRT, Hormone replacement therapy; OP, Osteoporosis; WHO, World
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Advanced Chronic Obstructive Pulmonary Disease (COPD) is
currently the second leading indication for lung trans-
plantation in the U.S., accounting for 27% of transplants in
2008.1 Lung transplantation in this population is often
performed with palliative intent as it infrequently improves
survival.2,3 Quality of life usually improves after lung
transplantation,3,4 but can become severely reduced by
osteoporotic fractures.5 Vertebral fractures associated with
OP can also significantly worsen lung function.6,7 An
accelerated loss of bone mineral density (BMD) and resul-
tant increased risk of fractures is known to occur early after
transplantation.8,9 Furthermore, osteoporosis (OP) is
a common and potentially serious complication of COPD,
estimated to occur in 6%e69% of patients depending in part
on the severity of illness.10
The basis for the increased risk of OP in COPD is not
completely understood. Contributing factors include oral
steroid use, physical inactivity, low BMI, reduced fat-free
mass, tobacco exposure, nutritional deficiencies including
vitamin D, advanced age, hormonal effects, and hypoxia.11
However, COPD appears to be an independent risk factor
for OP.12
Recent studies report a relationship between elevated
high density lipoprotein cholesterol (HDLc) levels and
osteoporosis in the general population.13e17 Whether
a relationship between HDLc and OP is present in COPD has
not been previously studied, but unusually high HDLc levels
have been reported in subjects with advanced COPD.18,19
Tisi described 29 men with COPD in whom HDLc levels
were compared to controls matched for age, obesity index,
alcohol intake, smoking history, and race. Mean HDLc
values were significantly elevated in the COPD subjects at
72  4 mg/dl vs. 54  3 mg/dl for controls.19 While Tisi’s
data found no correlation between HDLc and hypoxia,
Seishma compared 20 subjects with mixed lung disease
including emphysema, pulmonary fibrosis, and cystic
fibrosis against controls and found HDLc levels differed
from controls only in the subjects with hypoxemia.18 We
reviewed data from a cohort of advanced, primarily
hypoxemic, COPD patients evaluated for lung trans-
plantation to assess the relationship between HDLc with OP.
Methods
This study was approved by our institutional IRB. Consecu-
tive COPD patients referred to our center for consideration
of lung transplantation from 1995 to 2009 were screened.
Two hundred and ninety cases were reviewed and 45 were
excluded, yielding 245 records. Reasons for exclusion were
no diagnosis of COPD in 7, an additional lung disease in 28
and inadequate data in 16.
OP was defined either by bone mineral density (BMD) T-
score  2.5 via dual energy X-ray absorptiometry (DXA)
scanning, or use of bisphosphonate, teriparatide, or calci-
tonin therapy. DXA scanning is performed routinely as part
of the evaluation for lung transplantation, irrespective of
risk factors for OP. This case definition differs from that
suggested by the World Health Organization (WHO) of
a T-score below 2.5.20 T-scores represent standarddeviations from peak BMD adjusted for race and gender,
whereas Z-scores represent standard deviations from mean
BMD for a cohort the same race, gender, and age as the
patient. The WHO definition is an imperfect surrogate end
point relating to fracture risk. The proportion of fractures
attributable to OP based on the WHO definition of osteo-
porosis is modest, ranging from <10% to 44%.21 Many
experts now suggest case finding and treatment decisions
be based on risk assessment using the newer WHO FRAX
assessment tool which incorporates clinical risk factors with
BMD assessments to generate an estimate of 10 year frac-
ture risk.22 While this was beyond the scope of the data
available in this study, the addition of medication use in
case definitions has been validated in many chronic condi-
tions, including OP.23,24 As OP medication use could be
associated with increased clinical risk factors for fracture
and could also affect the measured BMD, those subjects
taking OP medications were considered as having OP
regardless of T-scores. Analysis of T-scores included eval-
uating the lowest T-score reported regardless of location,
consistent with current recommendations.25 Using this
definition of OP, determination as to the presence or
absence of OP could be made in 152 (62%) and this group
comprised the study cohort.
The following data were recorded: demographics,
anthropometrics, pulmonary function, medical comorbid-
ities, medications, fasting lipid profile values and DXA scan
results. Cardiovascular disease (CVD) was defined as
a history of congestive heart failure, stroke, peripheral
vascular disease, or coronary artery disease (CAD) included
in the medical history or found by coronary angiography
performed at the time of transplant evaluation.
Statistical analysis
Continuous data are expressed as mean (SD or range), and
categorical data are presented as counts and percentages.
Univariate analyses were made by Student t test, Chi2 test,
and Fisher’s exact tests as appropriate. Pearson correlation
coefficient was used to assess the relationship between
continuous variables. Several multiple linear regression
models were built to assess the relationship between
osteoporosis and variables found to be significant at the 0.1
level in univariate analyses or thought to be of clinical
importance. Reverse stepwise regression modeling was
performed with a p-value inclusion threshold of 0.2 to
generate the final multiple regression models. Underlying
modeling assumptions were checked graphically and
regression diagnostics were performed to assess for collin-
earity. Analysis was performed using Stata Statistical Soft-
ware, Release 10.0 (Stata Corporation; College Station,
TX).
Results
Of the 152 subjects included in the analysis, 116 (76%) had
osteoporosis. The diagnosis was based on a positive DXA
scan in 69 (59%) and medication use in 66 (57%). Thirty six
(31%) met both definitions. Ten patients (7%) with T-scores
above 2.5 were taking bisphosphonates or teriparatide
and were categorized as having OP. By study design, those
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scanning. Compared to the study cohort, the 93 patients
screened in whom the presence or absence of OP could not
be ascertained had a lower proportion of oral steroid use
[24% vs. 44%, (pZ 0.004)], higher FEV1% predicted [27% vs.
22%, (pZ 0.003)], and were much less frequently listed for
transplantation [3% vs. 59%, (p < 0.001)].
DXA scan results were available in 111 (73%) of the
cohort, Z-score reporting was available in 89 (59%). Of
those with DXA scans, 69 (62%) had osteoporosis, and
another 40 (36%) had osteopenia defined by T-scores of;
 1. Only 2 had normal BMD (Fig. 1). Z-scores also
demonstrated a considerably negative distribution (online
supplement). There was no statistically significant differ-
ence in the prevalence of osteoporosis, T-scores, or
Z-scores between genders. Table 1 lists the clinical char-
acteristics of subjects with and without osteoporosis. The
former group had lower BMI’s, worse pulmonary function,
and was less likely to be listed for transplant. Of subjects
with T-scores  2.5, 41% were supplemented with calcium
and vitamin D, 57% were receiving treatment with
a bisphosphonate, calcitonin, or teriparatide, and 35% took
nothing for bone health.
Oral steroids were being used by 48% of subjects in the
OP group at the time of evaluation, compared with 31% in
the no osteoporosis group (p Z 0.06). Among those taking
oral steroids, only 55% took calcium and vitamin D. Inhaled
steroid use was similar in the two groups at 76% and 75%,
respectively. Eleven percent of females in both groups were
on hormone replacement therapy.
The prevalence of CVD, CAD and other comorbidities
were similar, with the exception of a somewhat higher
proportion of systemic hypertension in the OP group
(Table 1). Invasive hemodynamic values were available in
101 patients and differed only by slightly lower right
ventricular pressures in patients with OP (online
supplement). Total cholesterol (TC) values were slightly
higher in the OP group, but HDLc was considerably
elevated, resulting in a lower TC/HDLc ratio. This rela-
tionship was not affected by statin use.
Clinical factors significantly associated with osteoporosis
by univariate analysis included BMI, FEV1 %predicted, DLCOFigure 1 Histogram demonstrating distribution of T-scores in
the study cohort. Osteopenia is defined as a T-score  1 and
osteoporosis is defined as a T-score  2.5.%predicted, and HDLc (Table 2). BMI correlated strongly
with T-scores (Fig. 2) and also correlated inversely with
HDLc (Fig. 3). An inverse linear correlation was observed
between HDLc and T-scores (rZ 0.21, pZ 0.05). Several
multivariate models were examined to assess the associa-
tions between clinical factors and osteoporosis. Clinical
factors examined included age, gender, BMI, HDLc, an
interaction term between HDLc and gender, oral steroid
use, FEV1 %predicted, and DLCO %predicted. In both step-
wise logistic regression and all other logistic regression
models examined, only BMI and HDLc remained indepen-
dent predictors of OP and contributed significantly to the
final multivariate model (Table 2). As bisphosphonates have
been shown to modestly increase HDLc levels,26 the final
multiple logistic regression model was repeated after
exclusion of all patients using bisphonates with virtually
identical results.
To examine the potential effect of increased BMI values
in the subjects with osteoporosis complicated by vertebral
fractures, the logistic regression model of HDLc and BMI as
predictor variables for OP was repeated with progressively
reduced BMI values in the subjects with osteoporosis to find
the threshold for statistical significance. This threshold
occurred at BMI values 1 point reduced from reported, with
greater reductions resulting in p-values above 0.05 for the
relationship between HDLc and osteoporosis.
We then examined the relationship between HDLc and OP
in males and females separately. In the entire cohort, mean
HDLc values were above normal in both men (64 25mg/dL)
and women (84  27 mg/dL). HDLc levels in females were
unchanged when those using hormone replacement therapy
(HRT)wereexcluded. Inbothgender groups,HDLcwashigher
in those with OP versus those without. Mean HDLc values
were 72  26 vs. 49  14 mg/dL (p Z 0.002) in males and
89  27 vs. 69  21 mg/dL (p Z 0.004) in females, respec-
tively (Fig. 4). The inverse linear correlation between HDLc
and T-scores for the entire group was heavily influenced by
a strong relationship among males (r Z 0.45; p Z 0.004)
(Fig. 5). Similarly, Z-scores correlated to HDLc levels only in
the males (rZ 0.41; pZ 0.02).
Discussion
Two important findings emerge from this study. First, the
prevalence of abnormal bone density is extremely high in
patients with advanced COPD referred for lung trans-
plantation. Second, elevated HDLc levels are significantly
and independently associated with osteoporosis in this
population, particularly among males. This is the first study
to assess the relationship between serum lipid values and
osteoporosis in COPD.
Prevalence of osteoporosis and osteopenia
Ourdata showanearly universal prevalenceof osteoporosis or
osteopenia in COPD lung transplant candidates. A prior study
estimated the prevalence of osteoporosis or osteopenia in
GOLD stage IV patients to be 75% with only 18% having oste-
oporosis.27 This study used quantitative ultrasound rather
than DXA scans and was limited to 28 patients in the stage IV
group. A meta-analysis including 775 patients found a 35%
Table 1 Clinical characteristics by osteoporosis status.a
Osteoporosis Absent (n Z 36) Osteoporosis Present (n Z 116) p-value
Age (yrs.) 55 (37e66) 57 (29e71) NS
Gender (% Male) 42% 37% NS
Race (% Caucasian) 92% 87% NS
BMI 28.5 (21e47) 23.2 (13e35) ***
Smoking history (pk-yrs) 59 (5e120) 51 (1e200) NS
Oxygen use (%) 86% 92% NS
Sucessfully listed (%) 75% 54% *
Transplanted (%) 33% 36% NS
Comorbidities
Cardiovascular disease (%) 36% 47% NS
Significant CADb (%) 26% 16% NS
Diabetes (%) 17% 9% NS
Hypertension (%) 33% 52% *
Oral steroid use 31% 48% 0.06
Statin use (%) 28% 31% NS
Lipid Profile (N Z 104)
Tot chol (mg/dL) 198 (147e300) 221 (122e413) *
TG (mg/dL) 155 (50e452) 120 (34e779) NS
LDL (mg/dL) 110 (40e185) 115 (41e237) NS
HDL (mg/dL) 60 (31e104) 83 (30e167) ***
TC/HDL 3.7 (1.9e6.6) 2.8 (1.5e6.4) **
DXA Scan Results (N Z 111)
Lowest T-scores 1.7 (2.47 to 0.7) 3.3 (5.8 to 1.1) ***
Lowest Z-scores 0.9 (2.2 to 0.1) 2.16 (4.1 to 0.1) ***
Lumbar T-score 0.8 (2.3 to 2) 2.7 (5.5 to 1.3) ***
Lumbar Z-score 0.02 (2.2 to 2.7) 1.6 (4.1 to 3) ***
Femoral neck T-score 1.5 (2.4 to 0.7) 2.7 (5.8 to 0.7) ***
Femoral neck Z-score 0.5 (1.7 to 0.3) 1.6 (3.9 to 0.3) ***
Trochanter T-score 0.9 (1.9 to 0.2) 2.2 (5.7 to 0) ***
Trochanter Z-score 0.4 (1.6 to 0.3) 1.5 (3.8 to 0.9) ***
Wards T-score 1.7 (2.47 to 0.7) 3 (5.5 to 1.2) ***
Wards Z-score 0.02 (1.6 to 1.5) 1.3 (3.3 to 0.8) ***
Total Hip T-score 0.9 (2.0 to 0.3) 2.3 (4.2 to 0.2) ***
Total Hip Z-score 0.3 (1.3 to 0.7) 1.5 (3.5 to 0.8) ***
Pulmonary Function (N Z 135)
FVC (% pred.) 55 (22e99) 47 (18e91) *
FEV1 (% pred.) 26 (10e73) 21 (6e47) **
DLCO (% pred.)c 45 (13e99) 36 (9e76) *
6MWD (m)d 279 (385e1556) 235 (257e1650) 0.09
*p  0.05, **p  0.01, ***P  0.001.
a Data are presented as mean (range), or as percentages.
b N Z 84. Defined as 50% stenosis in left main coronary, 70% elsewhere, or intervention performed.
c n Z 108.
d n Z 59.
1946 R.M. Reed et al.pooled prevalence of OP in COPD and observed worse
pulmonary function and lower BMI values in the subjects with
OP.10 The report included three studies involving COPD lung
transplant candidates10,27,28 in which the pooled prevalence
ofOPwas 55%. This value is similar to our observation amongst
subjects in whom T-scores were available in whom 62% had
osteoporosis and 98% had osteoporosis or osteopenia.
HDLc and bone mineral density
Prior studies examining the relationship between HDLc and
BMD have yielded conflicting results. A study of 13,970
young, highly active, Chinese subjects with a low prevalenceof OP found no relationship between total body BMD and
HDLc.29 A large, epidemiologic study of relatively young,
healthy subjects demonstrated a highly significant correla-
tion between HDLc and BMD by DXA in univariate analysis
which failed to persist after controlling for age, gender, and
BMI.30 A prospective study of 173 postmenopausal women
using highly selective selection criteria excluding most
medical comorbidities and BMI values outside a narrow range
similarly observed a correlation between HDLc and BMD
which did not persist after controlling for age, BMI, caloric
intake, and duration of menopause.15 In contrast, a study of
913 men and women exhibiting a relatively narrow range of
BMI found a relationship between HDLc and BMD which
Table 2 Logistic regression for osteoporosis.
Predictor Variable OR 95% CI p-value
Univariate Analysis
BMI 0.81 0.73e0.90 ***
FEV1% Pred 0.95 0.91e0.99 *
DLCO% Pred 0.98 0.95e0.998 *
HDL 1.04 1.02e1.07 ***
Oral steroid use 2.12 0.96e4.7 0.06
Age 1.04 0.99e1.1 NS
Female Gender 1.21 0.57e2.6 NS
Multiple Logistic Regression Modely
HDLc 1.03 1.004e1.053 *
BMI 0.81 0.72e0.92 ***
*p  0.05, **p  0.01, ***P  0.001.
y Age, gender, an interaction term between HDLc and gender, oral steroid use, FEV1 %predicted, and DLCO %predicted were examined
and found not to contribute significantly in multivariate modeling.
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composition.16 Another study of 214 postmenopausal Japa-
nese women found an association between HDLc and BMD
which persisted after controlling for age, BMI, and body
composition.17 Adami reported two Italian cohorts totalling
982 primarily older subjects in whomHDLc correlated to BMD
after controlling for age, BMI, and body composition.13 Most
recently, Buizert described a cohort of 1255 primarily elderly
men and women in whom HDLc correlated to BMD, which
persisted in the women after controlling for age, BMI,
smoking, physical activity, alcohol consumption, hyperten-
sion, and diabetesmellitus.14 Notably, the studies suggesting
an association between HDLc and BMD included older
subjects with more comorbidities.
A previously proposed mechanism to link bone and lipid
metabolism stems from the observation that osteoblasts
and adipocytes share a common bone marrow progenitor
cell and an inverse relationship between the commitment
of these bone marrow-derived mesenchymal stem cells to
the adipocyte versus osteoblast lineage pathways.14,31
Regulation of this process is complex and involves PPARg
as a key regulator of adipogenesis by promoting adipocyte
differentiation from these stem cells as well as inhibiting
osteoblast differentiation.32 HDLc may influence thisFigure 2 Pearson correlation between BMI and Lowest
T-score by DXA scan.process by removing oxygenated derivatives of cholesterol
from peripheral tissues. These oxysterols have been shown
to function synergistically with bone morphogenic protein-2
to induce osteogenic differentiation.33 Various lipoproteins,
including HDL, have also been shown to exert direct regu-
latory effects on osteoblasts,34 and osteoclasts.35,36
Leptin regulates bone formation in concert with the
sympathetic nervous system and has complex effects which
may lead to increased or decreased BMD.31,37 Leptin regu-
lates HDL metabolism,38 is inversely correlated with HDLc
and HDL apo-A1,39,40 and promotes bone formation through
effects on both osteoblasts, as well as osteoclasts.41,42
Certain leptin gene mutations are associated with
COPD,43 and leptin levels are decreased in COPD in
contradistinction to asthma in which they are elevated.44,45
Therefore, low leptin levels may contribute to both
increased HDLc as well as decreased bone mineral density.
Systemic steroids clearly decrease BMD and increase
fracture risk,46,47 and have been associated with higher
levels of HDLc.48 However, they do not explain all the
excess risk for OP as evidenced by abnormal bone metab-
olism and density in patients with COPD without exposure
to corticosteroids.49 While 44% of patients in our study were
taking oral steroids at the time of evaluation, informationFigure 3 Pearson correlation between BMI and HDL choles-
terol levels.
Figure 4 Box and whisker plot demonstrating HDL choles-
terol levels by Gender and Osteoporosis Status. HDLc values
differ by osteoporosis status in both men and women
(p < 0.005).
1948 R.M. Reed et al.pertaining to duration of use, dosing and intermittent use
was not available and may explain the insignificant p-value
of 0.06 comparing use between subjects with and without
osteoporosis.
Hypoxia was nearly universal in our study subjects and
may contribute to the association between elevated HDLc
and osteoporosis in patients with COPD. Hypoxia affects
HDLc metabolism via upregulation of plasma phospholipid
transfer protein,50 which transfers phospholipids between
lipoprotein particles and alters HDLc subfraction patterns.
Induced intermittent hypoxia has been shown to raise
HDLc in patients with coronary disease.51 Osteogenic
activity of preosteocyte-like cells is impaired in a hypoxic
environment,52 and hypoxia in animal models leads to
rapid bone resorption.53 Hypoxia also decreases the
mineralization potential of bone cells.52 Whether these
mechanisms apply to COPD patients is unproven, but the
relatively low rates of OP noted in non-hypoxemic
cohorts54 lend credence to the association.
A mechanism that may explain the gender difference in
the correlation between HDLc and BMD is male hypo-
gonadism. Male hypogonadism can result in decreased boneFigure 5 Pearson Correlation between lowest T-score vs.
HDL cholesterol in males and females.mineral density as well as elevated HDLc, and frequently
complicates systemic disease.55 While OP is generally more
common in women, our cohort was unusual in that men
demonstrated the same rates of OP as the women. The
prevalence of hypogonadism in males with COPD has been
estimated at 38%,56 although the cohort from which this
estimate was based had only moderate obstruction with
minimal hypoxemia. Hypogonadism in COPD is more
common with worsening hypoxemia, hypercarbia, steroid
use, severity of obstruction, exacerbations, and increased
inflammatory mediators such as IL-1, IL-6 and TNF-a.55,57
Furthermore, glucocorticoid use reduces adrenal and
gonadal hormones, including testosterone and estrogen.47
Study limitations
Due to the retrospective nature of this study, data per-
taining to fractures, fat-free mass, calcium intake, testos-
terone, vitamin D, and parathyroid hormone levels were
not available for analysis. Vertebral compression fractures
in subjects with osteoporosis would result in increased BMI
values. This would simultaneously weaken the correlation
between BMI and OP and strengthen the association
between HDLc and OP. However, our evaluation of the data
suggest the effect of vertebral fractures in the osteoporosis
group would have to exceed that sufficient to cause a mean
reduction in BMI of 1 point, which would equate to between
1.2 and 1.5 inches reduction in the osteoporosis group.
Vertebral fractures are common in severe COPD, as McEvoy
showed in a cohort of 312 men with COPD in which 63% of
patients using systemic steroids, and 49% of patients
despite no exposure to oral or inhaled steroids were found
to have vertebral fractures.58 Yamaguchi described
a difference of nearly an inch between subjects with and
without vertebral fractures.17 It is therefore likely that
vertebral compression fractures contribute to the associa-
tion between HDLc and OP independent of BMI, but do not
account for it entirely.
Conclusions
In lung transplant candidates with advanced COPD, reduced
bone mineral density is nearly universal. Low BMI is strongly
related to osteoporosis. High HDL cholesterol levels are
common in this population and are associated with osteo-
porosis independently of age, BMI, and severity of lung
disease. This association appears stronger among males.
Whether the elevated HDLc levels are directly involved in
the pathogenesis of OP or simply reflect the effects of
a common underlying process, such as hypogonadism,
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